Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics
Abstract Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.1%) is...
Saved in:
| Main Authors: | Laura M. Periman, Darrell E. White, Douglas Katsev |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-024-01076-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials
by: Ahmad M. Fahmy, et al.
Published: (2024-11-01) -
Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study
by: Jason Bacharach, et al.
Published: (2025-02-01) -
Investigating the Effect of Reducing the Signs and Symptoms of Lid Wiper Epitheliopathy in Patients With Dry Eye Disease With Perfluorohexyloctane
by: Chris Lievens, OD, MS, PhD, FNAP, FAAO, et al.
Published: (2025-01-01) -
Efficacy and Safety of 0.05 % Cyclosporine Ophthalmic Microemulsion for the treatment of Moderate to Severe Dry Eye Disease – an Indian Experience
by: Upsham Goel, et al.
Published: (2015-04-01) -
Early Adoption and Utilization of Perfluorohexyloctane for Dry Eye Disease in the United States
by: Shen Lee B, et al.
Published: (2025-07-01)